Blood biomarker studies have demonstrated that - amongst other plasma tau markers - tau phosphorylated at threonine-181 (p181) specifically captures AD brain pathology, and can differentiate AD from other neurodegenerative diseases [2, 18]. Here, MAPT is linked to neurodegenerative disease.